BMY Insider Trading
BRISTOL MYERS SQUIBB CO | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at BRISTOL MYERS SQUIBB CO provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 20:29 | 2026-04-01 | Elkins David V | Officer - EVP, Chief Financial Officer | SELL | $61.67 | 30,000 | $1,850,016 | 159,248 | -15.9% |
| 2025-09-04 01:46 | 2025-09-02 | Elkins David V | Officer - EVP, Chief Financial Officer | SELL | $47.33 | 56,000 | $2,650,480 | 167,379 | -25.1% |
| 2025-08-06 00:58 | 2025-08-02 | Short Bartie Wendy | Officer - EVP, Corporate Affairs | OPT+S | $44.23 | 378 | $16,719 | 5,066 | 0.0% |
| 2025-05-14 02:03 | 2025-05-09 | Hickey Benjamin | Officer - President, RayzeBio Org. | SELL | $38.01 | 97 | $3,702 | 0 | -100.0% |
| 2025-04-30 01:14 | 2025-04-25 | Hirawat Samit | Officer - EVP,Chief Med.Offr.,Drug Dev. | BUY | $47.58 | 4,250 | $202,215 | 83,513 | +5.4% |
| 2025-02-22 03:09 | 2025-02-20 | BOERNER CHRISTOPHER S. | Director, Officer - Chief Executive Officer | BUY | $55.05 | 2,000 | $110,096 | 104,626 | +1.9% |
| 2025-02-20 03:19 | 2025-02-14 | Hirawat Samit | Officer - EVP,Chief Med.Offr.,Drug Dev. | BUY | $54.84 | 1,823 | $100,000 | 63,932 | +2.9% |
| 2024-11-06 01:53 | 2024-11-04 | Holzer Phil M | Officer - SVP and Controller | SELL | $55.62 | 700 | $38,931 | 11,760 | -5.6% |
| 2024-11-06 01:41 | 2024-11-01 | Hirawat Samit | Officer - EVP,Chief Med.Offr.,Drug Dev. | BUY | $54.68 | 1,830 | $100,055 | 62,109 | +3.0% |
| 2023-12-08 02:06 | 2023-12-05 | BOERNER CHRISTOPHER S. | Officer - Chief Executive Officer | BUY | $49.78 | 2,000 | $99,560 | 82,672 | +2.5% |
| 2023-12-01 02:32 | 2023-11-28 | BOERNER CHRISTOPHER S. | Officer - Chief Executive Officer | BUY | $48.86 | 3,071 | $150,049 | 79,384 | +4.0% |
| 2023-11-22 03:01 | 2023-11-20 | Samuels Theodore R. II | Director | BUY | $49.81 | 8,500 | $423,385 | 35,500 | +31.5% |
| 2023-08-29 00:28 | 2023-08-24 | Powell Ann | Officer - EVP, Chief Human Resources | SELL | $61.25 | 17,986 | $1,101,643 | 27,868 | -39.2% |
| 2023-08-08 00:24 | 2023-08-03 | Plenge Robert M | Officer - EVP, Chief Research Officer | SELL | $61.14 | 732 | $44,754 | 6,584 | -10.0% |
| 2023-05-05 00:51 | 2023-05-03 | VESSEY RUPERT | Officer - EVP & President, Research | SELL | $67.06 | 50,385 | $3,378,818 | 47,751 | -51.3% |
| 2023-02-09 04:09 | 2023-02-06 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $74.65 | 240,000 | $17,916,000 | 236,104 | -50.4% |
| 2023-02-09 04:09 | 2023-02-06 | Powell Ann | Officer - EVP, Chief Human Resources | SELL | $74.69 | 11,183 | $835,258 | 23,043 | -32.7% |
| 2022-11-15 02:57 | 2022-11-09 | Powell Ann | Officer - EVP, Chief Human Resources | SELL | $80.45 | 16,250 | $1,307,313 | 34,226 | -32.2% |
| 2022-11-10 04:38 | 2022-11-07 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | OPT+S | $78.88 | 45,910 | $3,621,381 | 57,079 | 0.0% |
| 2022-09-23 00:12 | 2022-09-20 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $69.71 | 25,000 | $1,742,750 | 476,104 | -5.0% |
| 2022-09-17 00:12 | 2022-09-15 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $71.84 | 50,000 | $3,592,000 | 501,104 | -9.1% |
| 2022-09-16 02:29 | 2022-09-13 | Elkins David V | Officer - EVP, Chief Financial Officer | OPT+S | $71.30 | 133,951 | $9,551,162 | 119,786 | 0.0% |
| 2022-09-16 02:29 | 2022-09-14 | Powell Ann | Officer - EVP, Chief Human Resources | SELL | $70.75 | 25,000 | $1,768,750 | 50,476 | -33.1% |
| 2022-06-15 00:58 | 2022-06-13 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $74.04 | 30,000 | $2,221,200 | 551,104 | -5.2% |
| 2022-06-08 00:49 | 2022-06-06 | LEUNG SANDRA | Officer - EVP, General Counsel | SELL | $74.89 | 65,000 | $4,867,850 | 308,627 | -17.4% |
| 2022-03-24 02:43 | 2022-03-21 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $71.52 | 25,000 | $1,788,000 | 581,524 | -4.1% |
| 2022-03-19 00:50 | 2022-03-16 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | OPT+S | $69.25 | 74,559 | $5,162,972 | 50,385 | 0.0% |
| 2022-03-17 02:32 | 2022-03-14 | Santiago Karen Murphy | Officer - SVP & Controller | SELL | $69.20 | 6,577 | $455,096 | 16,704 | -28.3% |
| 2022-03-17 02:32 | 2022-03-14 | BOERNER CHRISTOPHER S. | Officer - EVP, Chief Commercial Officer | SELL | $69.20 | 29,532 | $2,043,526 | 41,966 | -41.3% |
| 2022-03-01 00:44 | 2022-02-24 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $67.00 | 30,000 | $2,010,000 | 453,455 | -6.2% |
| 2021-12-18 01:08 | 2021-12-16 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | SELL | $61.99 | 19,298 | $1,196,252 | 31,960 | -37.6% |
| 2021-11-25 01:25 | 2021-11-22 | von Autenried Paul | Officer - EVP, Chief Information Officer | SELL | $57.18 | 51,134 | $2,923,617 | 63,536 | -44.6% |
| 2021-09-23 00:19 | 2021-09-20 | Caforio Giovanni | Director, Officer - Board Chair and CEO | SELL | $60.64 | 25,000 | $1,516,000 | 483,980 | -4.9% |
| 2021-08-17 00:51 | 2021-08-12 | Elkins David V | Officer - EVP, Chief Financial Officer | OPT+S | $66.95 | 99,691 | $6,674,502 | 80,008 | 0.0% |
| 2021-08-04 23:47 | 2021-08-02 | Caforio Giovanni | Director, Officer - Chairman and CEO | SELL | $68.58 | 20,000 | $1,371,600 | 508,980 | -3.8% |
| 2021-08-04 23:46 | 2021-08-03 | Powell Ann | Officer - EVP, Chief Human Resources | SELL | $68.57 | 23,280 | $1,596,310 | 47,613 | -32.8% |
| 2021-08-03 23:56 | 2021-07-30 | Dubow Adam | Officer - SVP,ChiefCompliance&EthicsOff. | SELL | $67.90 | 2,466 | $167,441 | 13,777 | -15.2% |
| 2021-08-03 23:50 | 2021-07-30 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | OPT+S | $68.07 | 158,393 | $10,782,160 | 46,964 | 0.0% |
| 2021-08-03 23:49 | 2021-07-30 | von Autenried Paul | Officer - EVP, Chief Information Officer | SELL | $68.06 | 25,000 | $1,701,375 | 114,670 | -17.9% |
| 2021-08-03 23:54 | 2021-07-30 | LEUNG SANDRA | Officer - EVP, General Counsel | SELL | $68.04 | 29,390 | $1,999,696 | 339,967 | -8.0% |
| 2021-05-11 23:39 | 2021-05-10 | Eid Joseph | Officer - SVP,Head Glob. Medical Affairs | SELL | $65.00 | 1,118 | $72,670 | 8,069 | -12.2% |
| 2021-05-11 23:39 | 2021-05-10 | Schmukler Louis S | Officer - EVP,Pres.,Glob.Prod. & Supply | SELL | $65.25 | 15,000 | $978,750 | 31,956 | -31.9% |
| 2021-05-07 23:57 | 2021-05-05 | Dubow Adam | Officer - SVP,ChiefCompliance&EthicsOff. | SELL | $64.21 | 3,119 | $200,271 | 16,243 | -16.1% |
| 2021-05-07 23:56 | 2021-05-05 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | SELL | $64.29 | 30,546 | $1,963,802 | 45,139 | -40.4% |
| 2021-03-24 23:41 | 2021-03-22 | Caforio Giovanni | Director, Officer - Chairman and CEO | SELL | $62.20 | 25,000 | $1,555,000 | 528,980 | -4.5% |
| 2020-12-01 01:52 | 2020-11-25 | von Autenried Paul | Officer - EVP, Chief Information Officer | SELL | $63.50 | 3 | $191 | 126,698 | 0.0% |
| 2020-11-26 00:32 | 2020-11-23 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | SELL | $61.34 | 13,421 | $823,244 | 37,922 | -26.1% |
| 2020-11-26 00:32 | 2020-11-24 | Dubow Adam | Officer - SVP,ChiefCompliance&EthicsOff. | SELL | $63.39 | 900 | $57,051 | 15,186 | -5.6% |
| 2020-11-26 00:31 | 2020-11-24 | von Autenried Paul | Officer - EVP, Chief Information Officer | SELL | $62.75 | 20,000 | $1,255,000 | 126,701 | -13.6% |
| 2020-11-24 01:40 | 2020-11-19 | VESSEY RUPERT | Officer - EVP, Research & Early Dev. | OPT+S | $61.30 | 57,591 | $3,530,271 | 51,343 | 0.0% |
How to Interpret $BMY Trades
Not every insider transaction in BRISTOL MYERS SQUIBB CO is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $BMY shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for BMY
Insider activity data for BRISTOL MYERS SQUIBB CO is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $BMY, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.